MEI Pharma (MEIP) – PRNewswire
-
MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights
-
MEI Pharma to Present at Two Healthcare Conferences
-
MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021
-
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
-
MEI Pharma Announces Planned Chief Financial Officer Transition
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
-
MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib
-
MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting
-
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
-
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
-
MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer
-
MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval
-
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers
-
MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference
-
MEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical Models
-
MEI Pharma to present at the virtual H.C. Wainwright Global Life Sciences Conference 2021
-
MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights
-
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
-
MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights
-
MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences
-
Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma
-
MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing
-
MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights
-
MEI Pharma to Present at Upcoming Investor Conferences in September
-
MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide Corporate Update on September 9, 2020
-
MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020
-
MEI Pharma to Present at the Jefferies Virtual Healthcare Conference
-
MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program
-
MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress
-
Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes
-
MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data
-
MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights
-
MEI Pharma Appoints Cheryl Cohen, Product Launch and Commercialization Veteran, to its Board of Directors
-
MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401
-
MEI Pharma to Present at the 19th Annual Needham Virtual Healthcare Conference
-
MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma
-
MEI Pharma Reports Fiscal Second-Quarter 2020 Results and Operational Highlights
-
MEI Pharma Announces Closing of Public Offering of Common Stock
-
MEI Pharma Announces Pricing of Public Offering of Common Stock
-
MEI Pharma Announces Proposed Public Offering of Common Stock
-
MEI Pharma to Present at the Stifel 2019 Healthcare Conference
-
MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights
-
MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
-
MEI Pharma to Host Investor and Analyst Event on October 4, 2019
Back to MEIP Stock Lookup
